New Approaches to the Treatment of Heart Failure

[1]  Patrick W Serruys,et al.  Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. , 2003, Journal of the American College of Cardiology.

[2]  A. Bank,et al.  Efficacy and safety of sildenafil citrate in men with erectile dysfunction and congestive heart failure: a randomized placebo-controlled trial , 2003 .

[3]  B. Lewis,et al.  Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. , 2003, Journal of the American College of Cardiology.

[4]  C. O'connor,et al.  Vasopressin: a new target for the treatment of heart failure. , 2003, American heart journal.

[5]  M. Gheorghiade,et al.  Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.

[6]  D. Delurgio,et al.  Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure , 2003, Circulation.

[7]  P. Ponikowski,et al.  Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging , 2003, Circulation.

[8]  A. Hagège,et al.  Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. , 2003, Journal of the American College of Cardiology.

[9]  T Douglas Bradley,et al.  Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. , 2003, The New England journal of medicine.

[10]  V. Somers,et al.  Central Sleep Apnea in Left Ventricular Dysfunction: Prevalence and Implications for Arrhythmic Risk , 2003, Circulation.

[11]  M. Zile,et al.  Selective Matrix Metalloproteinase Inhibition With Developing Heart Failure: Effects on Left Ventricular Function and Structure , 2003, Circulation research.

[12]  C. Lang,et al.  Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure , 2003, Circulation.

[13]  Paul W Armstrong,et al.  Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure , 2003, Circulation.

[14]  W. Colucci,et al.  Sustained Hemodynamic Effects of Intravenous Levosimendan , 2003, Circulation.

[15]  A. Takeshita,et al.  Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction , 2002, Circulation.

[16]  E. Bocchi,et al.  Sildenafil Effects on Exercise, Neurohormonal Activation, and Erectile Dysfunction in Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Study Followed by a Prospective Treatment for Erectile Dysfunction , 2002, Circulation.

[17]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[18]  A. Struthers,et al.  Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure , 2002, Circulation.

[19]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[20]  G. Fonarow,et al.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. , 2002, Journal of the American College of Cardiology.

[21]  S. Archer,et al.  Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension Comparison With Inhaled Nitric Oxide , 2002 .

[22]  J. Ghali,et al.  Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure , 2001 .

[23]  D. Kass,et al.  Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy , 2001, Circulation.

[24]  Thomas Lavergne,et al.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay , 2001 .

[25]  F. Spinale,et al.  Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure , 2001, Circulation.

[26]  F. Ruschitzka,et al.  Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? , 2001, Journal of the American College of Cardiology.

[27]  D. Sawyer,et al.  Cell Therapy Attenuates Deleterious Ventricular Remodeling and Improves Cardiac Performance After Myocardial Infarction , 2001, Circulation.

[28]  J. Daubert,et al.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.

[29]  B. Bozkurt,et al.  Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure , 2001, Circulation.

[30]  K. Sliwa,et al.  Beneficial Effects of Pentoxifylline in Patients With Idiopathic Dilated Cardiomyopathy Treated With Angiotensin-Converting Enzyme Inhibitors and Carvedilol: Results of a Randomized Study , 2001, Circulation.

[31]  W. Abraham,et al.  Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). , 2000, Journal of cardiac failure.

[32]  T. Lüscher,et al.  Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.

[33]  S. Gottlieb,et al.  Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure , 2000, Circulation.

[34]  V. Dilsizian,et al.  Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease , 2000, Circulation.

[35]  W. Colucci,et al.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. , 2000, Circulation.

[36]  M. Pfeffer,et al.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial , 2000, The Lancet.

[37]  A. H. Garlick,et al.  The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. , 2000, Journal of the American College of Cardiology.

[38]  P. Rahko,et al.  Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. , 2000, Journal of the American College of Cardiology.

[39]  D. Singer,et al.  Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. , 2000, Circulation.

[40]  A. Logan,et al.  Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. , 2000, Circulation.

[41]  S. Gottlieb,et al.  Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. , 2000, Circulation.

[42]  R. Hajjar,et al.  Prospects for gene therapy for heart failure. , 2000, Circulation research.

[43]  J. Guerrero,et al.  Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Abraham,et al.  Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. , 1999, Journal of the American Society of Nephrology : JASN.

[45]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[46]  B. Bozkurt,et al.  Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.

[47]  A. H. Drummond,et al.  Preclinical and Clinical Studies of MMP Inhibitors in Cancer , 1999, Annals of the New York Academy of Sciences.

[48]  C. H. Chen,et al.  Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. , 1999, Circulation.

[49]  P. Hunziker,et al.  Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. , 1998, Circulation.

[50]  G. Maurer,et al.  Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. , 1998, Journal of the American College of Cardiology.

[51]  Y. Sun,et al.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.

[52]  D. Mann,et al.  Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. , 1998, Circulation.

[53]  S. Javaheri,et al.  Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. , 1998, Circulation.

[54]  W. Abraham,et al.  Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. , 1998, Journal of the American College of Cardiology.

[55]  D. Chatel,et al.  Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. , 1998, Circulation.

[56]  D. Fukai,et al.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[57]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[58]  P. Singal,et al.  Role of oxidative stress in transition of hypertrophy to heart failure. , 1996, Journal of the American College of Cardiology.

[59]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[60]  J. Levijoki,et al.  Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. , 1995, Journal of molecular and cellular cardiology.

[61]  P. Hunziker,et al.  Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.

[62]  S. Yusuf,et al.  Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction , 1995 .

[63]  J. Levijoki,et al.  Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation , 1995, Journal of cardiovascular pharmacology.

[64]  M. Kinoshita,et al.  Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. , 1994, Journal of the American College of Cardiology.

[65]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[66]  H. Herrmann,et al.  Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. , 1990, Circulation.

[67]  R. Cody,et al.  Plasma and Platelet Vasopressin in Essential Hypertension and Congestive Heart Failure , 1983, Hypertension.